Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.

Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH.

J Med Econ. 2012;15(6):1039-50. doi: 10.3111/13696998.2012.688903. Epub 2012 May 24.

PMID:
22533526
[PubMed - indexed for MEDLINE]
2.

Determining initial and follow-up costs of cardiovascular events in a US managed care population.

Chapman RH, Liu LZ, Girase PG, Straka RJ.

BMC Cardiovasc Disord. 2011 Mar 16;11:11. doi: 10.1186/1471-2261-11-11.

PMID:
21410963
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.

Chapman RH, Kowal SL, Cherry SB, Ferrufino CP, Roberts CS, Chen L.

Value Health. 2010 Sep-Oct;13(6):685-94. doi: 10.1111/j.1524-4733.2010.00774.x. Review.

PMID:
20825627
[PubMed - indexed for MEDLINE]
4.

Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.

Chapman RH, Yeaw J, Roberts CS.

BMC Cardiovasc Disord. 2010 Jun 17;10:29. doi: 10.1186/1471-2261-10-29.

PMID:
20565779
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.

Hussein MA, Chapman RH, Benner JS, Tang SS, Solomon HA, Joyce A, Foody JM.

Am J Cardiovasc Drugs. 2010;10(3):193-202. doi: 10.2165/11530680-000000000-00000.

PMID:
20387911
[PubMed - indexed for MEDLINE]
6.

The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*.

Chapman RH, Ferrufino CP, Kowal SL, Classi P, Roberts CS.

Int J Clin Pract. 2010 Jan;64(2):169-81. doi: 10.1111/j.1742-1241.2009.02196.x. Review.

PMID:
20089007
[PubMed - indexed for MEDLINE]
7.

Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?

Chapman RH, Pelletier EM, Smith PJ, Roberts CS.

Patient Prefer Adherence. 2009 Nov 3;3:265-75.

PMID:
19936170
[PubMed]
Free PMC Article
8.

Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.

Chapman RH, Petrilla AA, Berman L, Benner JS, Tang SS.

Am J Cardiovasc Drugs. 2009;9(5):299-308. doi: 10.2165/11312110-000000000-00000.

PMID:
19791839
[PubMed - indexed for MEDLINE]
9.

Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.

Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH.

Cardiovasc Diabetol. 2009 Sep 26;8:53. doi: 10.1186/1475-2840-8-53.

PMID:
19781099
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy.

Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS.

Am J Health Syst Pharm. 2009 Aug 15;66(16):1471-7. doi: 10.2146/ajhp080238.

PMID:
19667004
[PubMed - indexed for MEDLINE]
11.

Drug titration patterns and HbA 1c levels in type 2 diabetes.

Maclean JR, Chapman RH, Ferrufino CP, Krishnarajah G.

Int J Clin Pract. 2009 Jul;63(7):1008-16. doi: 10.1111/j.1742-1241.2009.02094.x.

PMID:
19570118
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Generic and therapeutic statin switches and disruptions in therapy.

Chapman RH, Benner JS, Girase P, Benigno M, Axelsen K, Liu LZ, Nichol MB.

Curr Med Res Opin. 2009 May;25(5):1247-60. doi: 10.1185/03007990902876271 .

PMID:
19344292
[PubMed - indexed for MEDLINE]
13.

Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study.

Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS.

Drugs Aging. 2008;25(10):885-92.

PMID:
18808213
[PubMed - indexed for MEDLINE]
14.

Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia.

Bays HE, Chapman RH, Fox KM, Grandy S; SHIELD Study Group.

Curr Med Res Opin. 2008 Apr;24(4):1179-86. doi: 10.1185/030079908X280527 . Epub 2008 Mar 14.

PMID:
18346311
[PubMed - indexed for MEDLINE]
15.

Quality of life and depression of people living with type 2 diabetes mellitus and those at low and high risk for type 2 diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD).

Grandy S, Chapman RH, Fox KM; SHIELD Study Group.

Int J Clin Pract. 2008 Apr;62(4):562-8. doi: 10.1111/j.1742-1241.2008.01703.x. Epub 2008 Feb 8.

PMID:
18266708
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes).

Bays HE, Bazata DD, Clark NG, Gavin JR 3rd, Green AJ, Lewis SJ, Reed ML, Stewart W, Chapman RH, Fox KM, Grandy S.

BMC Public Health. 2007 Oct 3;7:277.

PMID:
17915014
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys.

Bays HE, Chapman RH, Grandy S; SHIELD Investigators' Group.

Int J Clin Pract. 2007 May;61(5):737-47. Erratum in: Int J Clin Pract. 2007 Oct;61(10):1777-8.

PMID:
17493087
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Can we better prioritize resources for cost-utility research?

Neumann PJ, Rosen AB, Greenberg D, Olchanski NV, Pande R, Chapman RH, Stone PW, Ondategui-Parra S, Nadai J, Siegel JE, Weinstein MC.

Med Decis Making. 2005 Jul-Aug;25(4):429-36.

PMID:
16061895
[PubMed - indexed for MEDLINE]
19.

Predictors of adherence with antihypertensive and lipid-lowering therapy.

Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS.

Arch Intern Med. 2005 May 23;165(10):1147-52.

PMID:
15911728
[PubMed - indexed for MEDLINE]
20.

When does quality-adjusting life-years matter in cost-effectiveness analysis?

Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ.

Health Econ. 2004 May;13(5):429-36. Review.

PMID:
15127423
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk